Sign In
Buy CLPT
$14.94
+0.360 (+2.47%)
At Close: Jul 31, 2026
ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen
11:18pm, Thursday, 27'th Feb 2025
ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical
ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript
07:17pm, Wednesday, 26'th Feb 2025
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Misses Revenue Estimates
06:30pm, Wednesday, 26'th Feb 2025
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago.
ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results
04:05pm, Wednesday, 26'th Feb 2025
Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025
08:00am, Friday, 14'th Feb 2025
SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to t
ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula
04:15pm, Wednesday, 12'th Feb 2025
SOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to t
CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0
07:21am, Tuesday, 28'th Jan 2025
ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.
ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0
04:05pm, Monday, 27'th Jan 2025
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati
ClearPoint Neuro (CLPT) Surges 22.5%: Is This an Indication of Further Gains?
04:21am, Wednesday, 22'nd Jan 2025
ClearPoint Neuro (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
11:56am, Monday, 23'rd Dec 2024
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
06:15pm, Wednesday, 13'th Nov 2024
Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the
ClearPoint Neuro: Near-Term Volatility Is No Concern
09:35am, Sunday, 10'th Nov 2024
ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near
ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript
10:31pm, Thursday, 07'th Nov 2024
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Fi
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Tops Revenue Estimates
06:30pm, Thursday, 07'th Nov 2024
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.20 per share a year ago.
ClearPoint Neuro Reports Third Quarter 2024 Results
04:05pm, Thursday, 07'th Nov 2024
Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a glob
